Equities Analysts Issue Forecasts for ALDX Q2 Earnings

Aldeyra Therapeutics, Inc. (NASDAQ:ALDX) – Stock analysts at HC Wainwright raised their Q2 2026 earnings per share estimates for Aldeyra Therapeutics in a report released on Monday, May 11th. HC Wainwright analyst M. Caufield now forecasts that the biotechnology company will earn ($0.11) per share for the quarter, up from their previous estimate of ($0.16). HC Wainwright currently has a “Neutral” rating and a $2.00 target price on the stock. The consensus estimate for Aldeyra Therapeutics’ current full-year earnings is ($0.44) per share. HC Wainwright also issued estimates for Aldeyra Therapeutics’ Q3 2026 earnings at ($0.08) EPS, Q4 2026 earnings at ($0.19) EPS, FY2026 earnings at ($0.43) EPS, FY2027 earnings at ($0.22) EPS, FY2028 earnings at ($0.03) EPS and FY2030 earnings at $0.34 EPS.

Several other brokerages also recently issued reports on ALDX. Wall Street Zen downgraded Aldeyra Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday. BTIG Research reiterated a “buy” rating on shares of Aldeyra Therapeutics in a research report on Tuesday, March 17th. One research analyst has rated the stock with a Buy rating, two have given a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, Aldeyra Therapeutics has an average rating of “Hold” and a consensus target price of $5.50.

Aldeyra Therapeutics Trading Down 2.8%

Shares of NASDAQ ALDX opened at $1.71 on Wednesday. The stock has a 50 day simple moving average of $2.39 and a 200-day simple moving average of $4.10. The company has a market cap of $103.15 million, a PE ratio of -3.72 and a beta of 1.16. Aldeyra Therapeutics has a 12-month low of $1.07 and a 12-month high of $6.18.

Aldeyra Therapeutics (NASDAQ:ALDX) last posted its earnings results on Thursday, May 7th. The biotechnology company reported ($0.06) EPS for the quarter, beating the consensus estimate of ($0.13) by $0.07.

Insiders Place Their Bets

In other news, Director Richard Douglas bought 70,000 shares of the business’s stock in a transaction on Thursday, March 19th. The stock was purchased at an average cost of $1.40 per share, for a total transaction of $98,000.00. Following the completion of the transaction, the director directly owned 195,000 shares of the company’s stock, valued at approximately $273,000. This trade represents a 56.00% increase in their position. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. 8.50% of the stock is owned by company insiders.

Institutional Investors Weigh In On Aldeyra Therapeutics

A number of institutional investors have recently added to or reduced their stakes in ALDX. AQR Capital Management LLC lifted its position in Aldeyra Therapeutics by 456.3% in the first quarter. AQR Capital Management LLC now owns 392,555 shares of the biotechnology company’s stock worth $2,257,000 after purchasing an additional 321,992 shares during the period. Jacobs Levy Equity Management Inc. acquired a new stake in Aldeyra Therapeutics in the first quarter worth approximately $218,000. Jane Street Group LLC acquired a new stake in Aldeyra Therapeutics in the first quarter worth approximately $1,024,000. Acadian Asset Management LLC lifted its position in Aldeyra Therapeutics by 7,402.7% in the first quarter. Acadian Asset Management LLC now owns 95,960 shares of the biotechnology company’s stock worth $551,000 after purchasing an additional 94,681 shares during the period. Finally, Geode Capital Management LLC lifted its position in Aldeyra Therapeutics by 0.8% in the second quarter. Geode Capital Management LLC now owns 1,146,597 shares of the biotechnology company’s stock worth $4,392,000 after purchasing an additional 8,769 shares during the period. 59.71% of the stock is currently owned by institutional investors and hedge funds.

Key Stories Impacting Aldeyra Therapeutics

Here are the key news stories impacting Aldeyra Therapeutics this week:

• Neutral Sentiment: HC Wainwright raised near-term EPS estimates for Q2 2026 and Q3 2026, suggesting slightly better short-term expectations. MarketBeat ALDX page
• Neutral Sentiment: The firm also nudged FY2026 and FY2027 estimates higher and lifted its FY2030 outlook, indicating some longer-term improvement in the model. MarketBeat ALDX page
• Neutral Sentiment: However, HC Wainwright cut its Q4 2026 and FY2028 estimates, and it kept a Neutral rating with a $2.00 price target, which signals limited conviction in near-term upside. MarketBeat ALDX page

About Aldeyra Therapeutics

Aldeyra Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel small molecule therapies for immune-mediated diseases. The company’s research efforts center on targeted alkenals, a class of reactive aldehyde species that play a key role in inflammatory pathways. By selectively modulating these pathways, Aldeyra aims to address both ocular and systemic indications with high unmet medical need.

The company’s lead product candidate, reproxalap, is being investigated in several ophthalmic disorders, including dry eye disease, allergic conjunctivitis and non-infectious anterior uveitis.